Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Drug-eluting Balloon in Bifurcations Trial (DEBIUT)

This study has been completed.
Information provided by (Responsible Party):
Prof. Pieter Stella, UMC Utrecht Identifier:
First received: March 5, 2009
Last updated: July 16, 2015
Last verified: July 2015

The purpose of the DEBIUT study is to assess procedural, clinical and angiographic outcomes of:

  1. Provisional T-stenting use for dilation the Paclitaxel-eluting PCI-balloon (DiorTM) in comparison to dilation with a standard balloon prior to the implant of the Liberty Bare Metal Stent in bifurcation lesions (with side branch involvement).
  2. Comparison of the results above with the results of using a standard balloon prior to provisional T-stenting with the Paclitaxel-eluting stent TaxusTM LibertéTM.

Condition Intervention Phase
Coronary Artery Disease
Stable Angina
Unstable Angina
Device: Drug eluting balloon
Device: Liberté
Device: PTCA balloon catheter
Device: Taxus
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Three-arm Multi-center Study to Investigate Procedural, Clinical and Angiographic Outcomes Using a Drug Eluting Balloon Versus a Standard Balloon in Combination With a Bare Metal Stent and a DES Stent, Following the Provisional Side Branch T-stenting Approach, in Patients With Complex Lesions

Further study details as provided by UMC Utrecht:

Primary Outcome Measures:
  • Side branch angiographic Late Lumen Loss (expressed in millimeters) measured by Quantitative Coronary Analysis (QCA) [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Target vessel failure (TVF) [ Time Frame: 6 months ]
  • Major Angiographic coronary or cerebral Events (MACCE) [ Time Frame: 6 months ]

Enrollment: 120
Study Start Date: January 2008
Study Completion Date: January 2015
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Use of Dior balloon and implant of Liberté Bare Metal Stent
Device: Drug eluting balloon
Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
Other Name: Dior (EuroCor)
Device: Liberté
Bare metal stent
Other Name: Liberté (Boston Scientific)
Active Comparator: 2
Use of standard balloon and implant of Liberté Bare Metal Stent
Device: Liberté
Bare metal stent
Other Name: Liberté (Boston Scientific)
Device: PTCA balloon catheter
Percutaneous transluminal coronary angioplasty catheter
Other Name: Any PTCA catheter
Active Comparator: 3
Use of standard balloon and implant of Taxus Liberté Drug Eluting Stent
Device: PTCA balloon catheter
Percutaneous transluminal coronary angioplasty catheter
Other Name: Any PTCA catheter
Device: Taxus
Paclitaxel eluting stent
Other Name: Taxus Liberté (Boston scientific)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stable angina pectoris (CCS class 1,2,3,4) or unstable angina and documented ischemia or silent ischemia
  • Patients eligible for coronary revascularisation
  • The target bifurcation lesion has a major native coronary artery (>2.5mm) with a stenosis > 50% (on visual assessment) located at a side branch (>2mm)
  • Patient must be acceptable for CABG
  • De novo lesion
  • The main vessel lesion can be covered by one stent (up to 32mm)
  • Only one target lesion can be included in the study: other lesions in different vessels are successfully treated before the treatment of the target lesion (residual stenosis <30%, stent well deployed, no residual dissection, normal TIMI flow, no chest pain, ECG unchanged compared to pre-procedural ECG)
  • Signed patients informed consent

Exclusion Criteria:

  • Patient unable to give informed consent
  • Patients with a previous PCI in the target vessel
  • Patients with in stent restenosis of target lesion
  • Left ventricular ejection fraction more than 30%
  • Patients with left main disease
  • Severe calcifications with an undilatable lesion during balloon predilatation
  • History of bleeding diathesis
  • Untreated significant lesion greater than 50% diameter stenosis remaining proximal or distal to the target intervention.
  • Patient has suffered a stroke or TIA within the past 3 months
  • Life expectancy < 1 year
  • Any major surgery planned or required during the next 6 months
  • Acute Myocardial Infarction
  • Only one target lesion can be included in the study
  • Allergy to contrast and/or required anti-platelet medication
  • Patients unwilling to return for follow-up at 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00857441

Oost-Limburg Ziekenhuis
Genk, Belgium
Gasthuisberg Leuven
Leuven, Belgium
UMC Utrecht
Utrecht, Netherlands, 3584 cx
Sponsors and Collaborators
UMC Utrecht
Principal Investigator: Pieter Stella, MD UMC Utrecht
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Prof. Pieter Stella, Professor, UMC Utrecht Identifier: NCT00857441     History of Changes
Other Study ID Numbers: CRF8025
Study First Received: March 5, 2009
Last Updated: July 16, 2015

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Angina Pectoris
Angina, Stable
Angina, Unstable
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Chest Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms processed this record on April 26, 2017